A Safety, Tolerability, and Efficacy Study of IBI314 in Ambulatory Patients With COVID-19
Clinical trial NCT05162365 · TERMINATED
Trial details
- NCT number
- NCT05162365
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Status
- TERMINATED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-01-06
- Primary completion
- 2022-06-29
- Enrollment
- 248
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.